MetaCap

Silo Pharma (SILO) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Silo Pharma is the larger company by market cap ($3.7 million vs $3.4 million), about 1.1 times the size. XTL Biopharmaceuticals converts more of its revenue into profit, with a net margin of -227.7% versus -5863.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SILO+18.75%XTLB-30.81%
+36%+1%-34%
Oct 7, 20261 yearNov 20, 2026
SILO+16.33%XTLB-30.81%
+28%-3%-34%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SILO versus XTLB key metrics
MetricSILOXTLB
Share price$1.71$1.37
Market cap$3.69M$3.37M
1-day change-9.04%-5.84%
EPS (TTM)$-2.26$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.10K$451.00K
Revenue growth (YoY)0.00%—
Net income (latest FY)$-4.23M$-1.03M
Gross margin38.57%0.67%
Operating margin-5936.95%-481.60%
Net margin-5863.50%-227.72%
52-week high$10.43$5.64
52-week low$1.10$1.37
Distance from 52-week high-83.60%-75.71%
Average volume65.47K6.58K
Shares outstanding2.16M2.46M
Employees34
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XTL Biopharmaceuticals is more profitable, keeping -227.7 cents of every revenue dollar as net income versus -5863.5 cents for Silo Pharma.

About Silo Pharma

SILO stock →

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

SILO vs XTLB FAQ

Which is bigger, Silo Pharma or XTL Biopharmaceuticals?

Silo Pharma (SILO) is larger, with a market capitalization of $3.69M compared with $3.37M for XTL Biopharmaceuticals (XTLB).

Are Silo Pharma and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons